Printer Friendly

AMERICAN BIOGENETIC SCIENCES, INC. AND MEDEVA PLC TO DEVELOP NEW HEPATITIS A VACCINE

 NEW YORK, Dec. 11 /PRNewswire/ -- American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA) announced today that it has entered into an agreement with Medeva PLC (Medeva) pursuant to which ABS has granted Medeva a two year option to acquire a license for the worldwide rights to a Hepatitis A vaccine based on ABS' proprietary technology. In connection with the option agreement, ABS and Medeva will work together to develop the vaccine. The option is exercisable until Jan. 6, 1995. If Medeva exercises the option to enter into the license, it will pay ABS $2.5 million, plus ongoing royalties. The rate of such royalties will depend upon the annual volume of Medeva's vaccine sales, reaching as high as 15 percent on sales in excess of $50 million.
 In addition, Medeva has agreed to purchase 200,000 shares of newly issued Class A common stock from ABS in January, 1993, at a cash price of $7.50 per share, for an aggregate of $1.5 million.
 The vaccine being developed by ABS is a new recombinant vaccine for Hepatitis A, a disease which is prevalent worldwide and is endemic in some areas. Hepatitis A virus is similar to polio but affects the liver rather than the central nervous system. The worldwide market for a Hepatitis A vaccine is estimated at approximately $300 million per annum.
 Until recently, the only way to prevent Hepatitis A was to administer a dose of immune globulin before the disease had been contracted. Recently, a killed whole virus vaccine product was developed. A Hepatitis A vaccine based on ABS' technology is believed to have significant advantages over the killed whole virus vaccine and immune globulin in that:
 -- it will offer long-term protection to members of high-risk groups.
 -- as a recombinant vaccine, it is potentially safer than a killed whole virus vaccine.
 -- each course of treatment should involve only two doses.
 -- it is relatively easy to produce.
 Medeva also believes that there may be a potential to develop a mucosally delivered form of ABS' Hepatitis A vaccine. This form, if developed, should bring the further advantages of improved patient acceptability. The addition of a Hepatitis A vaccine would complement Medeva's product range, which presently includes a range of injected and orally delivered travel vaccines.
 Mr. Alfred J. Roach, chairman and founder of ABS, said, "I am particularly pleased about this agreement with Medeva. They are a young, dynamic company with a growing position in vaccines and we are impressed with their technical skills and marketing ability."
 American Biogenetic Sciences, Inc., is a biopharmaceutical company which conducts research to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease and the early diagnosis of Alzheimer's disease. These antibodies are produced from the company's proprietary germ-free and antigen-free mouse colony. The company is also conducting research in the area of early breast cancer detection.
 Medeva is an international pharmaceutical company and the fifth largest vaccine manufacturer in the world. Medeva is a high growth company that manufactures prescription pharmaceuticals, comprising a range of branded products, vaccines and unbranded generics.
 -0- 12/11/92
 /CONTACT: Fran Giambanco, senior vice president of American Biogenetic Sciences, Inc., 516-789-2600/
 (MABXA)


CO: American Biogenetic Sciences, Inc.; Medeva PLC IN: New York IN: MTC SU:

PS-LR -- NY006 -- 6118 12/11/92 09:18 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1992
Words:551
Previous Article:SHAW INDUSTRIES COMPLETES PUBLIC OFFERING
Next Article:THE LIPOSOME COMPANY ANNOUNCES FINAL PHASE II STUDY RESULTS WITH TLC D-99
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES RECEIVES U.S. PATENT FOR BLOOD CLOT DETECTION ANTIBODY
SOCIETE GENERALE SECURITIES CORPORATION & HEALTHCARE CAPITAL GROUP APPOINTED AMERICAN BIOGENETIC SCIENCES FINANCIAL ADVISORS
SOCIETE GENERALE SECURITIES AND HEALTHCARE CAPITAL GROUP SPONSORING AMERICAN BIOGENETIC SCIENCES PRESENTATION TO MEET NEW COMPANY PRESIDENT
ARMSTRONG PHARMACEUTICALS INC. AND MEDEVA PLC COMPLETE MERGER
AMERICAN BIOGENETIC SCIENCES REPORTS AGREEMENT WITH NEW ENGLAND DEACONESS HOSPITAL AND HARVARD MEDICAL SCHOOL FOR CLINICAL EVALUATION OF 'SOLFIB,'...
VAXCEL ANNOUNCES LICENSE AGREEMENT WITH CORIXA
Tiny Nasdaq Company Has Breakthrough Technology of Extreme Importance In Prevention, Diagnosis And Treatment Of Cancer, Alzheimer's, Strokes And...
PowderJect Announces Revised Agreement With Aviron for FluMist(TM) Influenza Vaccine Securing Income of $35 Million.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters